David E. I. Pyott, chief executive of Allergan, spent a couple of hectic days in Manhattan last week paying calls on institutional investors and Wall Street analysts, trying to persuade them that his company is worth much more than $54 billion. Since April, Allergan has been trying to fend off a takeover attempt by Valeant Pharmaceuticals International, a serial acquirer of specialty drug makers.
Allergan, defending its Fort Botox
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.